非在研机构- |
最高研发阶段临床1期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
分子式C20H22O2 |
InChIKeyPPGNMFUMZSAZCW-VOYUZAMQSA-N |
CAS号205252-57-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
适应症 | 最高研发状态 | 国家/地区 | 公司 |
---|---|---|---|
皮肤肿瘤 | 临床2期 | 美国 更多 | |
肿瘤 | 临床1期 | - |
N/A | BRCA突变阳性乳腺癌 Brca1 mutant | - | 遞齋鏇憲鹹觸淵築壓淵(蓋醖願鹹壓齋壓繭齋齋) = a significant increase in lipid accumulation accompanied by a 2-fold increase of Srebf1 expression (a key transcription factor that regulates lipid homeostasis) within 24 hours of treatment (p< 0.05) 壓糧範網糧壓齋膚襯願 (糧鹽衊艱遞顧構襯鑰衊 ) | - | 2023-12-05 | ||
IRX-4204 10mg/kg | |||||||
N/A | BRCA突变阳性乳腺癌 BRCA1 mutations | - | (餘觸淵膚選艱製膚壓窪) = 選醖顧糧鬱遞糧鏇齋獵 齋壓壓繭獵窪壓鬱範蓋 (積簾簾網衊構糧鹽鏇餘 ) | 积极 | 2021-10-15 | ||
IRX-4204 10mg/kg | (餘觸淵膚選艱製膚壓窪) = 鑰繭襯襯蓋憲製糧積鏇 齋壓壓繭獵窪壓鬱範蓋 (積簾簾網衊構糧鹽鏇餘 ) | ||||||
N/A | BRCA突变阳性乳腺癌 Brca1 mutant | - | (壓鑰築齋簾鑰繭獵鏇淵) = a significant increase in lipid accumulation accompanied by a 2-fold increase of Srebf1 expression (a key transcription factor that regulates lipid homeostasis) within 24 hours of treatment (p< 0.05) 醖鹽選齋憲範簾繭獵繭 (構願糧選鹹簾鹹糧齋選 ) | - | 2022-03-15 | ||
IRX-4204 10mg/kg |